Investors
We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.
Second Quarter 2025
Second quarter 2025 results were reviewed by management during a live audio webcast with the financial community on July 31, 2025. The presentation was followed by a Q&A session.
Press Releases
July 31, 2025
Press release: Online availability of Sanofi’s half-year financial report for 2025
July 31, 2025
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
July 30, 2025
Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Upcoming Events
30th Consecutive Year of Dividend Increase
Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00